Skip to main content
NCBI home page
Gut logoLink to Gut
. 1998 Jun;42(6):761–763. doi: 10.1136/gut.42.6.761

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

S RILEY 1
PMCID: PMC1727139  PMID: 9691909

Full Text

The Full Text of this article is available as a PDF (65.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azad Khan A. K., Howes D. T., Piris J., Truelove S. C. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut. 1980 Mar;21(3):232–240. doi: 10.1136/gut.21.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. BARON J. H., CONNELL A. M., LENNARD-JONES J. E., JONES F. A. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962 May 26;1(7239):1094–1096. doi: 10.1016/s0140-6736(62)92080-9. [DOI] [PubMed] [Google Scholar]
  4. Bilyard K. G., Joseph E. C., Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol Suppl. 1990;172:52–55. doi: 10.3109/00365529009091911. [DOI] [PubMed] [Google Scholar]
  5. Campieri M., Gionchetti P., Belluzzi A., Brignola C., Tampieri M., Iannone P., Miglioli M., Barbara L. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991 Aug;32(8):929–931. doi: 10.1136/gut.32.8.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Campieri M., Lanfranchi G. A., Boschi S., Brignola C., Bazzocchi G., Gionchetti P., Minguzzi M. R., Belluzzi A., Labò G. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut. 1985 Apr;26(4):400–405. doi: 10.1136/gut.26.4.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DICK A. P., GRAYSON M. J., CARPENTER R. G., PETRIE A. CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS. Gut. 1964 Oct;5:437–442. doi: 10.1136/gut.5.5.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. De Vos M., Verdievel H., Schoonjans R., Praet M., Bogaert M., Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut. 1992 Oct;33(10):1338–1342. doi: 10.1136/gut.33.10.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dew M. J., Harries A. D., Evans N., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):23–24. doi: 10.1136/bmj.287.6384.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dissanayake A. S., Truelove S. C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973 Dec;14(12):923–926. doi: 10.1136/gut.14.12.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fockens P., Mulder C. J., Tytgat G. N., Blok P., Ferwerda J., Meuwissen S. G., Tuynman H. A., Dekker W., Gasthuis K., van Hees P. A. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol. 1995 Nov;7(11):1025–1030. doi: 10.1097/00042737-199511000-00003. [DOI] [PubMed] [Google Scholar]
  12. Giaffer M. H., Holdsworth C. D., Lennard-Jones J. E., Rodrigues C. A., McIntyre P. B., Manjunatha S., Baron J. H., Barrison I. G., Polson R. J., Hoare A. M. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther. 1992 Aug;6(4):479–485. doi: 10.1111/j.1365-2036.1992.tb00561.x. [DOI] [PubMed] [Google Scholar]
  13. Green J. R., Lobo A. J., Holdsworth C. D., Leicester R. J., Gibson J. A., Kerr G. D., Hodgson H. J., Parkins K. J., Taylor M. D. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 1998 Jan;114(1):15–22. doi: 10.1016/s0016-5085(98)70627-4. [DOI] [PubMed] [Google Scholar]
  14. Green J. R., Swan C. H., Rowlinson A., Gibson J. A., Brown P., Kerr G. D., Swarbrick E. T., Thornton P. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther. 1992 Oct;6(5):647–652. doi: 10.1111/j.1365-2036.1992.tb00578.x. [DOI] [PubMed] [Google Scholar]
  15. Greenfield S. M., Punchard N. A., Teare J. P., Thompson R. P. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993 Aug;7(4):369–383. doi: 10.1111/j.1365-2036.1993.tb00110.x. [DOI] [PubMed] [Google Scholar]
  16. Ireland A., Priddle J. D., Jewell D. P. Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci (Lond) 1990 Jan;78(1):105–111. doi: 10.1042/cs0780105. [DOI] [PubMed] [Google Scholar]
  17. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  18. MOERTEL C. G., BARGEN J. A. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis. Ann Intern Med. 1959 Nov;51:879–889. doi: 10.7326/0003-4819-51-5-879. [DOI] [PubMed] [Google Scholar]
  19. Mahmud N., Stinson J., O'Connell M. A., Mantle T. J., Keeling P. W., Feely J., Weir D. G., Kelleher D. Microalbuminuria in inflammatory bowel disease. Gut. 1994 Nov;35(11):1599–1604. doi: 10.1136/gut.35.11.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mantzaris G. J., Hatzis A., Petraki K., Spiliadi C., Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum. 1994 Jan;37(1):58–62. doi: 10.1007/BF02047216. [DOI] [PubMed] [Google Scholar]
  21. Marshall J. K., Irvine E. J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997 Jun;40(6):775–781. doi: 10.1136/gut.40.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Novis B. H., Korzets Z., Chen P., Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988 May 21;296(6634):1442–1442. doi: 10.1136/bmj.296.6634.1442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pamukcu R., Hanauer S. B., Chang E. B. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 1988 Oct;95(4):975–981. doi: 10.1016/0016-5085(88)90172-2. [DOI] [PubMed] [Google Scholar]
  24. Powell-Tuck J., MacRae K. D., Healy M. J., Lennard-Jones J. E., Parkins R. A. A defence of the small clinical trial: evaluation of three gastroenterological studies. Br Med J (Clin Res Ed) 1986 Mar 1;292(6520):599–602. doi: 10.1136/bmj.292.6520.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Riley S. A., Lloyd D. R., Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut. 1992 Oct;33(10):1348–1352. doi: 10.1136/gut.33.10.1348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Riley S. A., Tavares I. A., Bishai P. M., Bennett A., Mani V. Mesalazine release from coated tablets: effect of dietary fibre. Br J Clin Pharmacol. 1991 Aug;32(2):248–250. doi: 10.1111/j.1365-2125.1991.tb03891.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Riley S. A., Turnberg L. A. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Q J Med. 1990 Jun;75(278):551–562. [PubMed] [Google Scholar]
  28. Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J., Koval G., Nichols T., Targan S., Fleishman C. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997 Oct;92(10):1867–1871. [PubMed] [Google Scholar]
  29. Schreiber S., Hämling J., Zehnter E., Howaldt S., Daerr W., Raedler A., Kruis W. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997 Jun;40(6):761–766. doi: 10.1136/gut.40.6.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sutherland L. R., May G. R., Shaffer E. A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. doi: 10.7326/0003-4819-118-7-199304010-00009. [DOI] [PubMed] [Google Scholar]
  31. Taffet S. L., Das K. M. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci. 1983 Sep;28(9):833–842. doi: 10.1007/BF01296907. [DOI] [PubMed] [Google Scholar]
  32. Travis S. P., Tysk C., de Silva H. J., Sandberg-Gertzén H., Jewell D. P., Järnerot G. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut. 1994 Sep;35(9):1282–1286. doi: 10.1136/gut.35.9.1282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Turunen U., Elomaa I., Anttila V. J., Seppälä K. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol. 1987 Sep;22(7):798–802. doi: 10.3109/00365528708991917. [DOI] [PubMed] [Google Scholar]
  34. d'Albasio G., Pacini F., Camarri E., Messori A., Trallori G., Bonanomi A. G., Bardazzi G., Milla M., Ferrero S., Biagini M. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997 Jul;92(7):1143–1147. [PubMed] [Google Scholar]
  35. van Hogezand R. A., van Hees P. A., van Gorp J. P., van Lier H. J., Bakker J. H., Wesseling P., van Haelst U. J., van Tongeren J. H. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988 Feb;2(1):33–40. doi: 10.1111/j.1365-2036.1988.tb00668.x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES